Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Avidity Biosciences (NASDAQ: RNA) intends to adjourn its February 23, 2026 special meeting and reconvene on February 26, 2026 at 10:00 a.m. ET, to allow additional time to satisfy conditions for a pro rata distribution of SpinCo shares (Atrium Therapeutics) required for the Merger.
The Distribution is expected on February 26, 2026, the Merger closing is expected on February 27, 2026, and Avidity common stock will temporarily trade under RNAM on Nasdaq beginning the Distribution date. Record date remains January 29, 2026.
Avidity Biosciences (Nasdaq: RNA) announced Phase 1/2 MARINA results for delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 (DM1) published in The New England Journal of Medicine on Feb 19, 2026. Treated participants showed an average ~40% reduction in DMPK mRNA and improvements in splicing, myotonia, muscle strength, mobility, and patient-reported function. Del-desiran had an acceptable safety profile overall; two serious adverse events occurred, one deemed drug-related and one led to discontinuation. The 4 mg/kg dose is in the global Phase 3 HARBOR study; topline 54-week readout expected in H2 2026.
Avidity Biosciences (Nasdaq: RNA) announced a record date of February 12, 2026 (close of business ET) for the pro rata distribution of Atrium Therapeutics common stock in a Spin-Off tied to the proposed Novartis acquisition.
Holders will receive one share of SpinCo per ten Avidity shares. Completion of the Merger and Spin-Off remains subject to closing conditions and Avidity stockholder approval; the Record Date may change based on the closing date.
Toll Brothers (NYSE:TOL) announced Enclave by Toll Brothers, a 35‑home luxury single‑family community coming to Corona, California, with site work underway at Santana Way and Garretson Ave and sales anticipated to begin in early fall 2026. Homes will feature one‑ and two‑story plans with up to 5 bedrooms, 4.5–5.5 baths, 2–4 car garages, and personalization via the Toll Brothers Design Studio. Community amenities include a park with green space, lounge seating and a BBQ area. The location offers access to hiking, shopping, dining and schools in the Corona‑Norco Unified School District. Contact (866) 232‑1631 or TollBrothers.com/CA for the interest list.
Avidity Biosciences (Nasdaq: RNA) announced a U.S. Managed Access Program (MAP) to provide investigational delpacibart zotadirsen (del-zota) to eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) under an FDA-authorized treatment protocol.
Enrollment is anticipated to begin by year-end 2025, and participants in EXPLORE44-OLE may transition to the MAP after completing two years of treatment. Avidity aligned with FDA after an October 2025 pre-BLA meeting and plans a BLA submission in 2026 seeking accelerated approval; patients would move to commercial supply if approved. Full MAP eligibility details will be posted on clinicaltrials.gov.
Avidity Biosciences (Nasdaq: RNA) announced a definitive merger agreement with Novartis valuing the company at about $12 billion, with closing expected in H1 2026 following the separation of early-stage cardiology programs into a new public SpinCo.
The company reported clear FDA alignment after an October 2025 pre-BLA meeting for del-zota, plans a 2026 BLA submission, and highlighted one-year data showing sustained muscle protection and reversal of disease progression. Del-zota holds Breakthrough Therapy designation.
Financials: cash and marketable securities of approximately $1.9 billion (9/30/25), expected to fund operations to mid-2028; Q3 collaboration revenue included a $10.0M milestone; Q3 R&D and G&A expenses rose materially versus 2024.
Avidity Biosciences (NASDAQ:RNA) has entered into a definitive merger agreement to be acquired by Novartis for USD 72.00 per share in cash, valuing Avidity at approximately USD 12.0 billion on a fully diluted basis. The deal prices Avidity at ~46% above the October 24, 2025 close and ~62% above the 30-day VWAP.
Prior to closing, Avidity will spin out its early-stage precision cardiology programs into a new public company ("SpinCo") capitalized with USD 270 million; SpinCo leadership and board roles are specified. The transaction includes three late-stage neuroscience programs being acquired by Novartis. Closing is expected in 1H 2026, subject to the SpinCo separation, regulatory approvals and stockholder approval.
Avidity Biosciences (Nasdaq: RNA) said management will participate in a panel at the Chardan 9th Annual Genetic Medicines Conference in New York on Oct 21, 2025 at 11:00 a.m. PT / 2:00 p.m. ET. A live webcast, event details, and an archived replay will be available on the company's Investors > Events and Presentations webpage.
This is a scheduled investor-conference panel appearance; no financial or clinical data, guidance, or transactions were announced.
Avidity Biosciences (Nasdaq: RNA) announced a positive pre-BLA meeting with the U.S. FDA for delpacibart zotadirsen (del-zota) in Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44). The company updated its planned BLA submission timing to Q1 2026 (previously year-end 2025) to provide additional CMC data requested by FDA. Del-zota holds Breakthrough Therapy designation; Avidity plans this as the first of three BLA submissions over a 12-month period and is preparing a confirmatory study for full approval.
Avidity Biosciences (NASDAQ: RNA) will present late-breaking oral and poster data from the EXPLORE44 clinical development program for delpacibart zotadirsen (del-zota) at the 30th Annual World Muscle Society Congress in Vienna, October 7-11, 2025.
The company said the presentations build on September 2025 results that showed reversal of disease progression and improvements versus baseline and natural history in multiple functional measures after one year of continuous treatment in Phase 1/2 EXPLORE44 and Phase 2 EXPLORE44-OLE in Duchenne muscular dystrophy patients amenable to exon 44 skipping (DMD44). Del-zota is investigational and not approved by the FDA.
Oral presentation: Kevin M. Flanigan, M.D., on October 11, 2025, 12:33–12:45 p.m. CET. Poster 674P: Aravindhan Veerapandiyan, M.D., on October 8, 2025, 2:30–3:30 p.m. CET. Slides and poster will be posted on the company publications page.